Colorado Chromatography

What Colorado Chromatography does

Colorado Chromatography Labs is a U.S.-based contract research organization (CRO) and early-stage drug discovery lab operating from Golden, Colorado, with a stated headcount of 11-50 employees. The company delivers three core research service lines — natural product chemistry, analytical method development (HPLC to LC-MS), and in-vitro bioassays — to academic institutions, biotech firms and startups, and the cannabinoid industry, monetizing work through project-based contracts and collaborative research agreements rather than disclosed product pricing. Its technical stack is anchored in chromatography-based purification, GC-MS, HPLC, UV-Vis, microplate readers, and computational tools such as StarDrop for predictive docking and structure-based drug design.

Beyond services, Colorado Chromatography has built an internal therapeutic research portfolio spanning Kratom alkaloid encapsulation, kavalactone formulation, cannabinoid derivative toxicology, a kinome screening platform, and novel kinase inhibitor synthesis. Its most differentiated assets are three preclinical pipeline compounds — CCL-106, CCL-114, and CCL-115 — cannabinoid-derived redox-disruption agents targeting pancreatic ductal adenocarcinoma (PDAC), with reported approximately 50% tumor volume reduction in MIA PaCa-2 CDX models and 48% reduction (p<0.001) in resistant PC041917 PDX models when combined with standard-of-care chemotherapy. The company frames its oncology work as a systems-biology approach to the PDAC tumor microenvironment, including stromal composition, immune suppression, and metabolic coupling.

The go-to-market is sales-led and content-driven: direct engagement with research teams, an educational blog, LinkedIn presence, and email newsletter aimed at academic and industry research partners. The company is privately held, founder-led, and reports no disclosed venture capital, private equity, parent entity, or public funding rounds.

Name

Colorado Chromatography

Legal name

Colorado Chromatography Labs

Website

https://coloradochromatography.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Colorado Chromatography Labs is a U.S. CRO and early-stage drug discovery lab in Golden, Colorado, providing natural product chemistry, analytical method development, and in-vitro bioassays to academic, biotech, and cannabinoid-industry clients, while advancing a preclinical PDAC pipeline (CCL-106, CCL-114, CCL-115).

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract research services
• Natural product chemistry
• Analytical method development
• Preclinical drug discovery
• Pharmaceutical contract research

Headquarters

HQ city

Parker

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: The company operates as a contract research organization (CRO) providing research services to academic institutions, biotech firms, and startups. Services include natural product chemistry, analytical method development, toxicology screening, and custom synthesis. Revenue is generated through project-based contracts and collaborative research agreements with external organizations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Colorado Chromatography Labs operates as a Contract Research Organization providing pharmaceutical-grade minor cannabinoid manufacturing, natural product synthesis, analytical method development, and in-vitro bioassays for biotech firms, academic institutions, and the cannabinoid industry. The company maintains an internal research pipeline of pre-clinical drug candidates targeting pancreatic ductal adenocarcinoma (PDAC) through proprietary redox-disruption platforms including CCL-106, CCL-114, and CCL-115. Services span chemical biology, structure-based drug design, and biological systems analysis.

Product overview

Colorado Chromatography Labs is a cutting-edge R&D organization specializing in chemical biology, natural product synthesis, and biological testing. The company operates as a research services provider with a portfolio of research service lines (Natural Product Chemistry, Analytical Method Development, In-Vitro Bioassays) and active research projects spanning oncology (Kinome Screening Platform, Novel Kinase Inhibitor Synthesis, CCL-106, CCL-114/CCL-115) and botanical therapeutics (Kratom Alkaloid Encapsulation, Kavalactone Formulation, Crude Kratom Separation). The company also conducts Cannabinoid Derivative Toxicology research. Their pipeline compounds CCL-106, CCL-114, and CCL-115 represent a differentiated approach targeting redox balance in PDAC tumors rather than single pathway inhibition.

Differentiator

Problem solved

Functional benefit

Products and services

• Natural Product Chemistry Synthesis, isolation, and characterization of natural product compounds for biotech, academic, and cannabinoid-industry clients seeking natural-product-derived starting points for drug discovery.
• Analytical Method Development Chromatography-based analytical method development and validation services supporting purity assessment, characterization, and quality control of natural product and cannabinoid samples.
• In-Vitro Bioassays Biological assay services used to evaluate pharmacological activity, toxicity, and mechanism of action of natural product and small-molecule candidates.
• Kavalactone Formulation Formulation development and encapsulation work for kavalactones, leveraging the company's proprietary encapsulation methods for natural product actives.
• Cannabinoid Derivative Toxicology Toxicology assessment services for cannabinoid derivatives, supporting safety characterization of minor cannabinoid and semisynthetic cannabinoid compounds.
• Kinome Screening Platform Kinome-wide screening service to profile kinase inhibitor activity and selectivity, applicable to PDAC discovery projects and external client engagements.
• Crude Kratom Separation Chromatographic separation and purification of crude kratom material into individual alkaloid fractions for research and characterization.
• Novel Kinase Inhibitor Synthesis Custom medicinal chemistry synthesis of novel kinase inhibitor compounds for client-led and internal PDAC drug discovery programs.

Quantifiable outcome

• Approximately 50% tumor volume reduction in MIA PaCa-2 CDX PDAC model with CCL-106 treatment
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Partnerships

Two partnerships are on record, tiered core.

• Academic InstitutionscoreStrategic or Co-development PartnerEngages in joint research, data sharing, and co-authored publications with universities and medical research centers for natural product chemistry and therapeutic discovery collaborations.
• Industry PartnerscoreStrategic or Co-development PartnerCollaborates with industry partners including biotech firms and startups for contract research, innovation projects, and scale-up initiatives in drug discovery and development.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• InMed Pharmaceuticals: Clinical-stage biopharmaceutical company developing cannabinoid-based therapeutics, with a similar hybrid model of cannabinoid pharmaceutical R&D. Highly comparable in cannabinoid therapeutic pipeline focus.
• Artelo Biosciences: Clinical-stage biotech developing cannabinoid-inspired therapeutics for cancer, inflammation, and CNS disorders. Directly comparable as a small-cap cannabinoid-derived oncology pipeline company.
• Cannabics Pharmaceuticals: Early-stage cannabinoid drug discovery company focused on personalized medicine and cannabinoid-based cancer therapeutics. Comparable in botanical/cannabinoid oncology orientation and company scale.
• Frontage Laboratories: Contract research organization providing analytical, formulation, and preclinical services to pharma and biotech. Directly comparable as a mid-sized CRO with similar analytical and formulation capabilities.
• Anresco Laboratories: Independent analytical testing laboratory serving the cannabis and food industries. Comparable as a smaller analytical-services CRO operating in the regulated botanical/cannabinoid testing space.

Broad incumbents

• Eurofins Discovery: Large CRO offering discovery, in-vitro pharmacology, and analytical services including natural product testing. Comparable as a CRO providing the same service categories (analytical method development, in-vitro bioassays, medicinal chemistry) at greater scale.
• Charles River Laboratories: Global CRO with discovery services, safety assessment, and in-vitro pharmacology capabilities. Comparable across in-vitro bioassay, analytical, and discovery CRO service lines at substantially greater scale and breadth.
• WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and analytical services to pharma/biotech. Comparable as a competing CRO with overlapping analytical method development, in-vitro bioassay, and discovery chemistry capabilities.
• Mirati Therapeutics: Oncology-focused biotechnology company developing targeted therapies including for pancreatic cancer indications. Comparable as a competing PDAC therapeutic developer, though at substantially more advanced clinical stage.

Regional players

• PharmaCann: Vertically integrated cannabis company with research and product development operations. Comparable as a cannabinoid-industry counterpart investing in pharmaceutical-grade cannabinoid formulation and safety testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ColoradoCBN

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Colorado Chromatography